Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Temozolomide 5Radiotherapy 4Carmustine 3Surgical Procedures, Operative 2Hyperbaric Oxygenation 2Ethanol 2Carboplatin 2pembrolizumab 1lonafarnib 1ipatasertib 1interleukin-4-Pseudomonas exotoxin 1dactolisib 1Verteporfin 1Tamoxifen 1Procarbazine 1Phosphorus-32 1Pemetrexed 1Neoadjuvant Therapy 1Lomustine 1Erlotinib Hydrochloride 1Dihematoporphyrin Ether 1Chlorotoxin 1Chemotherapy, Adjuvant 1Brachytherapy 1Arsenic Trioxide 17-tert-butyldimethylsilyl-10-hydroxycamptothecin 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Gliosarcoma × ipatasertib × Clear all
NCT02430363 2016-02-24

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Medical Research Council

Phase 1/2 Unknown
58 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡